Teva Pharmaceuticals is the leading generic drug company in the United States. In 2011, Teva accounted for 17.1% of US generic prescriptions, with 1 of every 6* US generic prescriptions being filled with a Teva product. Teva introduced 16 generic products in 2011, with 162 ANDAs pending FDA approval as of May 15, 2012. The company markets the broadest product line in the industry, with nearly 400 generic products in over 1200 dosage strengths and packaging sizes, covering all major therapeutic categories.
The Global Leader
Teva’s parent company, Teva Pharmaceutical Industries Ltd, is a global organization that combines the world’s leading generics business with a world-class specialty pharmaceutical business. The company’s mission is to provide a broad range of affordable and effective medicines to patients around the world. Teva operates in approximately 60 countries, and has 56 finished dosage pharmaceutical manufacturing sites, 21 API production sites, and 17 pharmaceutical R&D centers around the world. Approximately 48% of the company’s revenue is generated in the United States.
Expanding Branded Pharmaceuticals
In addition to its leadership in the generics market, Teva has a significant and growing branded pharmaceutical portfolio. Teva has branded products in several therapeutic classes, including CNS, respiratory, women’s health, and oncology. Brands currently on the market include COPAXONE®, AZILECT®, NUVIGIL®, ProAir®, TREANDA®, and a sizeable women’s health portfolio. Additionally, the company has over 40 products in various stages of clinical development.
Invested in Biosimilars
Teva has identified biopharmaceuticals—in particular, biosimilars—as an important long-term growth opportunity, and has established a dedicated research, development, and manufacturing infrastructure. The company’s joint venture with Switzerland-based Lonza Group Ltd provides access to the expertise and infrastructure of the world’s largest producer of biological API. Teva’s biopharmaceutical R&D facilities specialize in various technologies, including the proprietary albumin fusion technology, which can be used to create long-acting biological products.
Leading the Way to Affordable Health Care
Teva’s vision is to make quality health care accessible. The company’s Government Affairs team occupies an office on Capitol Hill and works on behalf of American consumers to advance both innovation and patient access to needed therapies. Teva launched the Smart-Health.com website, where patients can learn about generic pharmaceuticals and why they are an important element of high-quality, affordable health care. Teva is the leading provider of affordable generic medicines. Its robust pipeline of future products is a source of continuing value to American consumers.
For more information, visit tevausa.com